Scientific Consulting · Translational Medicine
Ph.D. — Biochemistry & Molecular Biology
Translational neuroscience scientist specializing in biomarker strategy, multi-omics, and drug development. Twenty years at the intersection of lipidomics, metabolomics, and clinical science — turning complex biology into decisions that advance therapies.
I founded MyMetabolome to bring senior-level scientific expertise directly to the organizations that need it — without the overhead of a large consultancy. My work sits at the intersection of lipid biology, multi-omics mass spectrometry, and translational drug development.
Over two decades I have built omics platforms and biomarker programs from the ground up at Denali Therapeutics and Arkuda Therapeutics, advancing assets through proof-of-concept in Alzheimer's, Parkinson's, lysosomal storage disorders, and neuroinflammation. I have led CRO partnerships, shaped regulatory-facing evidence packages, and worked cross-functionally with clinical, regulatory, and bioinformatics teams.
What sets my work apart is depth in lipid biology — an area of rapidly growing importance across neurodegeneration, metabolic disease, and rare disorders — combined with the strategic and leadership experience to translate that science into portfolio-level decisions.
I also hold an adjunct faculty position at Georgetown University, where I lead NIH- and Alzheimer's Association-funded research and mentor the next generation of translational scientists.
Senior scientific expertise delivered directly — from early biomarker strategy through clinical execution and beyond.
End-to-end biomarker planning for clinical programs — defining MOA, pharmacodynamic, and patient stratification endpoints. Study design, protocol input, and regulatory-facing evidence packages.
Design and oversight of lipidomics, metabolomics, and proteomics workflows using LC-MS/MS and immunoassay platforms (Olink, SomaLogic). Targeted and untargeted approaches across plasma, CSF, serum, and tissue.
Fit-for-purpose assay development and validation for translational and clinical biomarker readouts. CRO selection, oversight, and quality management to ensure regulatory-ready data.
Hypothesis generation, experimental strategy, and study design for preclinical-to-clinical translation. Integration of multi-omics datasets with clinical endpoints and disease biology.
Strategic scientific input for drug development programs, pipeline decisions, and portfolio planning. Expert review of biomarker plans, regulatory documents, and clinical protocols.
Scientific writing, grant strategy, and publication support for academic and industry partners. Experienced in NIH, foundation, and industry-sponsored research frameworks.
Two decades spanning academia, CRO, and biopharma — from platform building to senior program leadership.
I work with biotech and pharma companies at any stage — from early platform strategy to late-phase clinical biomarker execution. If you're looking for senior scientific expertise in lipidomics, metabolomics, or translational biomarker strategy, I'd welcome a conversation.